Table 2.

Invasive Disease–free Survival, According to Recurrence Score and Treatment (Intention-to-Treat Population).^*

Recurrence-Score Category and Type of Therapy	No. of Participants	Invasive Disease-free Survival at 5 Yr	Hazard Ratio for Recurrence (95% CI)†
		percent
Premenopausal women
≤10, endocrine only	174	92.4±2.2	0.47 (0.18–1.20)
≤10, chemoendocrine	151	96.6±1.7
11–15, endocrine only	277	93.3±1.7	0.68 (0.33–1.37)
11–15, chemoendocrine	287	95.5±1.4
16–20, endocrine only	254	83.8±2.6	0.57 (0.35–0.94)
16–20, chemoendocrine	269	91.5±1.9
21–25, endocrine only	118	85.2±3.6	0.63 (0.30–1.31)
21–25, chemoendocrine	121	92.4±2.8
Women ≤50 yr
≤10, endocrine only	145	91.0±2.6	0.31 (0.10–0.94)
≤10, chemoendocrine	135	97.9±1.5
11–15, endocrine only	247	93.1±1.8	0.71 (0.33–1.51)
11–15, chemoendocrine	235	95.4±1.6
16–20, endocrine only	227	85.1±2.6	0.58 (0.33–1.00)
16–20, chemoendocrine	224	92.2±2.0
21–25, endocrine only	107	80.0±4.3	0.56 (0.27–1.17)
21–25, chemoendocrine	98	90.0±3.6
Postmenopausal women
≤10, endocrine only	434	92.7±1.4	0.72 (0.44–1.18)
≤10, chemoendocrine	434	92.7±1.4
11–15, endocrine only	454	95.8±1.0	1.30 (0.88–1.92)
11–15, chemoendocrine	524	93.5±1.2
16–20, endocrine only	525	90.8±1.5	0.91 (0.57–1.43)
16–20, chemoendocrine	454	93.2±1.3
21–25, endocrine only	451	93.2±1.3	1.13 (0.75–1.70)
21–25, chemoendocrine	255	84.8±2.5
Women >50 yr
≤10, endocrine only	463	93.1±1.3	0.78 (0.48–1.26)
≤10, chemoendocrine	472	95.5±1.0
11–15, endocrine only	554	93.6±1.1	1.22 (0.83–1.79)
11–15, chemoendocrine	577	91.2±1.4
16–20, endocrine only	481	92.1±1.3	0.86 (0.56–1.32)
16–20, chemoendocrine	496	92.8±1.3
21–25, endocrine only	266	86.9±2.3	1.17 (0.77–1.76)
21–25, chemoendocrine	246	81.8±2.7

^*Plus–minus values are means ±SE.

^†A hazard ratio of less than 1 indicates a higher recurrence rate with endocrine therapy only than with chemoendocrine therapy.